Emami Q1FY27: Revenue up 15% to ₹1,039 Cr; Acquires full control of Axiom Ayurveda, majority in IncNut
Emami Limited reported a 15% consolidated revenue growth to ₹1,039 crore for Q1FY27. Domestic business grew 20%, with strategic investments portfolio up 61%. The company acquired full control of Axiom Ayurveda and a majority stake in IncNut. EBITDA grew 6% to ₹226 crore, and PBT increased 4% to ₹195 crore.
The results show robust growth and strategic acquisitions that significantly enhance the company's market presence and future growth potential.
The company reported strong revenue growth, driven by its domestic business and strategic investments, despite challenging market conditions. Key acquisitions further strengthen its market position.
Emami Limited announced its unaudited financial results for the first quarter ended June 30, 2026, reporting a resilient 15% growth in consolidated revenues to ₹1,039 crore. The domestic business demonstrated strong performance, growing by 20% on a reported basis and 12% on a like-to-like basis, with an 8% volume growth. This growth was driven by key categories such as Hair & Scalp Care, which grew by 11%, and Skin Care and Health Care, which grew by 3% and 2% respectively. The strategic investments portfolio was a standout performer, achieving a 61% like-to-like growth and now contributing 18% to the domestic business.
Organized channels continued to gain traction, growing by 19% and accounting for 32% of the domestic business. The company's omnichannel strategy is proving effective, with Quick Commerce contributing 35% of e-commerce sales.
Despite disruptions in West Asia leading to a 12% decline in international business, the underlying strength of the franchise remains intact. The company faced challenging operating conditions with elevated input costs due to inflation and higher crude oil prices, which led to a contraction in gross margins by 360 basis points to 65.8%. Nevertheless, EBITDA grew by 6% to ₹226 crore and Profit Before Tax (PBT) increased by 4% to ₹195 crore, supported by disciplined cost management and operational efficiencies.
Strategic investments were a key focus during the quarter. Emami increased its stake in Axiom Ayurveda (AloFrut), making it a wholly-owned subsidiary, and acquired a majority stake in IncNut, strengthening its presence in the personalized beauty and personal care segment through brands like Vedix and SkinKraft.
Looking ahead, Emami anticipates benefiting from healthy demand trends and continued momentum in its strategic investment businesses in Q2FY27. The company remains optimistic about its growth prospects, positioning itself for sustained and profitable growth through its diversified portfolio, strengthened distribution, robust innovation, and disciplined cost management.
What to do with a filing like this
Emami Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emami Limited. Read the original for the full detail.